An interventional study of CGBio stent and Biomatrix flex in Ischemic Heart Disease, Stable Coronary Artery Disease and Stable Angina, sponsored by CGBio Inc.. Status unknown at 1 site in Korea, Republic of. Open to participants aged 20 Years to 80 Years. Per ClinicalTrials.gov, last updated 2017-03-28.
Sponsored by CGBio Inc. · Not applicable, Interventional, and Treatment
Among 61 studies in Myocardial Ischemia with a site in Korea, Republic of — 13 open to participants now, 17 under way, none of them phase 3. Myocardial Ischemia · Korea, Republic of.
Among the 61 studies in Myocardial Ischemia with a site in Korea, Republic of, this one is the 21st largest by planned enrollment of the 30 interventional ones that give a count, is one of 4 that started in 2017, is one of 19 with no phase, and was the 32nd registered.
1,123 studies on the registry are indexed under Myocardial Ischemia; 177 are open to participants now.
Browse Myocardial Ischemia studies →13 of the 61 studies in Myocardial Ischemia with a site in Korea, Republic of are open now. Recruiting first, the newest first:
Yonsei University · Sites in Korea, Republic of
Samsung Medical Center · Sites in Korea, Republic of
Konkuk University Medical Center · Sites in Korea, Republic of
Saint Vincent's Hospital, Korea · Sites in Korea, Republic of
Yonsei University · Sites in Korea, Republic of
A study can be open while its sites in Korea, Republic of have not opened yet or have stopped. Only those recruiting at a site in Korea, Republic of →
Of the 135 Myocardial Ischemia studies recruiting now, 92 (68%) set no upper age limit and 6 (4%) stop at 75 or younger; 14 take children under 18; 20 take healthy volunteers.
This study: 20 Years to 80 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
61 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 3 · Phase 3 1 · Phase 4 5
First in 2007; this study’s year is marked. 4 started in 2017.
This study's planned enrollment of 112 is close to the median of 116 across 622 interventional studies indexed under Myocardial Ischemia.
Median enrollment 209 across the 30 interventional studies, 1,080 across the 31 observational. Of the 32 that completed or were terminated, 4 (13%) have results posted.
This tab as a report to print or save as PDF → With an account.
7 of 61 have an industry lead sponsor. The 10 most frequent:
CGBio Inc. is the lead sponsor of 7 studies on the registry; 2 are open to participants now.
CGBio Inc. has 1 study filed under Myocardial Ischemia — fewer than ten, so there is no comparison to draw.
4 of the studies in Myocardial Ischemia with a site in Korea, Republic of that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05682118Yonsei UniversityImpact of Dynamic CoROnary RoADmap System for Guidance of Instantaneous Wave-Free Ratio or Fractional Flow Reserve | 2026-11-27 |
| NCT05044273Jung-min AhnEvaluation of Effectiveness and Safety of Synergy XD and Synergy Megatron™ Stent | 2026-12-31 |
| NCT05846893B. Braun Medical Industries Sdn. Bhd.Drug-Coated Balloon vs. Drug-Eluting Stent for Clinical Outcomes in Patients With Large Coronary Artery Disease | 2027-05 |
| NCT05444452Samsung Medical CenterGENOSS Coronary Stent Clinical Trial | 2027-06-30 |
Among the 61 studies in Myocardial Ischemia with a site in Korea, Republic of, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
to evaluate safety and efficacy of CGBIO stent(DES) compared to Biomatrix flex stent(DES)
A Multicenter, subject-blinded, randomized study to evaluate safety and efficacy of CGBIO stent compared to Biomatrix Flex stent in patients undergoing drug-eluting stent procedure after coronary angiography
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The Co-Cr biodegradable polymer DES Sirolimus DRUG Ascorbic Acid(Vitamin C)
Device: CGBio stent
The abluminal biodegradable polymer DES BA9™ (BIOLIMUS A9™) DRUG
Device: Biomatrix flex
Percutaneous Coronary Intervention
Percutaneous Coronary Intervention
in-segment late loss
angiographic in-segment late loss measure by QCA program
Time frame: 9 month
in-stent late loss
angiographic in-stent late loss measure by QCA program
Time frame: 9 month
MACE
death, MI and TVF
Time frame: 9 month
Restenosis rate
angiographic restenosis rate
Time frame: 9month
Plan to share: No
No publications or documents are linked to this record.
Started Mar 2017 (actual). Primary completion is estimated for Sep 2017, 6 months after the start.
Of 37 industry-sponsored interventional studies with no phase under Myocardial Ischemia, half reached primary completion within 34 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 58. This study's planned 6 months is below that.
Counting every sponsor, half of 192 studies reached it within 34 months; a quarter within 15 and three quarters within 58.
How these figures are worked out, and which studies are left out of them.
This study is status unknown, as verified in Mar 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
CGBio Inc.